Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Carl Atkinson and Stephen Tomlinson.
Connection Strength

5.786
  1. Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury. Circulation. 2015 Mar 31; 131(13):1171-80.
    View in: PubMed
    Score: 0.509
  2. Donor brain death exacerbates complement-dependent ischemia/reperfusion injury in transplanted hearts. Circulation. 2013 Mar 26; 127(12):1290-9.
    View in: PubMed
    Score: 0.444
  3. Targeted complement inhibitors protect against posttransplant cardiac ischemia and reperfusion injury and reveal an important role for the alternative pathway of complement activation. J Immunol. 2010 Dec 01; 185(11):7007-13.
    View in: PubMed
    Score: 0.377
  4. Complement-dependent inflammation and injury in a murine model of brain dead donor hearts. Circ Res. 2009 Nov 20; 105(11):1094-101.
    View in: PubMed
    Score: 0.351
  5. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol. 2008 Jan 15; 180(2):1231-8.
    View in: PubMed
    Score: 0.312
  6. Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol. 2006 Nov 15; 177(10):7266-74.
    View in: PubMed
    Score: 0.287
  7. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest. 2005 Sep; 115(9):2444-53.
    View in: PubMed
    Score: 0.264
  8. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation. Front Immunol. 2021; 12:785229.
    View in: PubMed
    Score: 0.204
  9. In Situ Pre-Treatment of Vascularized Composite Allografts With a Targeted Complement Inhibitor Protects Against Brain Death and Ischemia Reperfusion Induced Injuries. Front Immunol. 2021; 12:630581.
    View in: PubMed
    Score: 0.199
  10. Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope. J Heart Lung Transplant. 2021 10; 40(10):1112-1121.
    View in: PubMed
    Score: 0.198
  11. A novel injury site-natural antibody targeted complement inhibitor protects against lung transplant injury. Am J Transplant. 2021 06; 21(6):2067-2078.
    View in: PubMed
    Score: 0.193
  12. C3a receptor antagonism as a novel therapeutic target for chronic rhinosinusitis. Mucosal Immunol. 2018 09; 11(5):1375-1385.
    View in: PubMed
    Score: 0.160
  13. Natural immunoglobulin M initiates an inflammatory response important for both hepatic ischemia reperfusion injury and regeneration in mice. Hepatology. 2018 02; 67(2):721-735.
    View in: PubMed
    Score: 0.155
  14. Natural IgM antibodies that bind neoepitopes exposed as a result of spinal cord injury , drive secondary injury by activating complement. J Neuroinflammation. 2017 06 19; 14(1):120.
    View in: PubMed
    Score: 0.150
  15. Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy. Transplantation. 2017 04; 101(4):e75-e85.
    View in: PubMed
    Score: 0.147
  16. Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement. J Neuroinflammation. 2015 Dec 30; 12:247.
    View in: PubMed
    Score: 0.135
  17. Dissecting the complement pathway in hepatic injury and regeneration with a novel protective strategy. J Exp Med. 2014 Aug 25; 211(9):1793-805.
    View in: PubMed
    Score: 0.123
  18. The alternative complement pathway propagates inflammation and injury in murine ischemic stroke. J Immunol. 2012 Nov 01; 189(9):4640-7.
    View in: PubMed
    Score: 0.108
  19. Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis. J Immunol. 2012 Jun 15; 188(12):6309-18.
    View in: PubMed
    Score: 0.105
  20. A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer. Blood. 2012 Jun 21; 119(25):6043-51.
    View in: PubMed
    Score: 0.104
  21. Pathogenic natural antibodies propagate cerebral injury following ischemic stroke in mice. J Immunol. 2012 Feb 01; 188(3):1460-8.
    View in: PubMed
    Score: 0.102
  22. The alternative and terminal pathways of complement mediate post-traumatic spinal cord inflammation and injury. Am J Pathol. 2010 Dec; 177(6):3061-70.
    View in: PubMed
    Score: 0.094
  23. Ketamine-xylazine-acepromazine compared with isoflurane for anesthesia during liver transplantation in rodents. J Am Assoc Lab Anim Sci. 2010 Jan; 49(1):45-51.
    View in: PubMed
    Score: 0.089
  24. A role for complement in the enhanced susceptibility of steatotic livers to ischemia and reperfusion injury. J Immunol. 2009 Oct 01; 183(7):4764-72.
    View in: PubMed
    Score: 0.087
  25. A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J Clin Invest. 2009 Aug; 119(8):2304-16.
    View in: PubMed
    Score: 0.086
  26. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol. 2008 Dec 01; 181(11):8068-76.
    View in: PubMed
    Score: 0.083
  27. Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection. Int J Cancer. 2008 Sep 15; 123(6):1357-63.
    View in: PubMed
    Score: 0.082
  28. Modulation of protective T cell immunity by complement inhibitor expression on tumor cells. Cancer Res. 2008 Aug 15; 68(16):6734-42.
    View in: PubMed
    Score: 0.081
  29. A complement C3 inhibitor specifically targeted to sites of complement activation effectively ameliorates collagen-induced arthritis in DBA/1J mice. J Immunol. 2007 Dec 01; 179(11):7860-7.
    View in: PubMed
    Score: 0.077
  30. Complement plays an important role in spinal cord injury and represents a therapeutic target for improving recovery following trauma. Am J Pathol. 2006 Sep; 169(3):1039-47.
    View in: PubMed
    Score: 0.071
  31. Complement inhibition alleviates donor brain death-induced liver injury and posttransplant cascade injury by regulating phosphoinositide 3-kinase signaling. Am J Transplant. 2023 Feb 04.
    View in: PubMed
    Score: 0.055
  32. Crosstalk between pro-survival sphingolipid metabolism and complement signaling induces inflammasome-mediated tumor metastasis. Cell Rep. 2022 12 06; 41(10):111742.
    View in: PubMed
    Score: 0.055
  33. Targeting the Complement Alternative Pathway Permits Graft Versus Leukemia Activity while Preventing Graft Versus Host Disease. Clin Cancer Res. 2020 07 01; 26(13):3481-3490.
    View in: PubMed
    Score: 0.045
  34. Complement C3a and C5a receptors promote GVHD by suppressing mitophagy in recipient dendritic cells. JCI Insight. 2018 12 20; 3(24).
    View in: PubMed
    Score: 0.042
  35. Memory CD4+ T cells are suppressed by CD8+ regulatory T cells in vitro and in vivo. Am J Transl Res. 2017; 9(1):63-78.
    View in: PubMed
    Score: 0.036
  36. New therapeutic and diagnostic opportunities for injured tissue-specific targeting of complement inhibitors and imaging modalities. Semin Immunol. 2016 06; 28(3):260-7.
    View in: PubMed
    Score: 0.035
  37. A Targeted Inhibitor of the Alternative Complement Pathway Accelerates Recovery From Smoke-Induced Ocular Injury. Invest Ophthalmol Vis Sci. 2016 Apr; 57(4):1728-37.
    View in: PubMed
    Score: 0.034
  38. Targeting complement component 5a promotes vascular integrity and limits airway remodeling. Proc Natl Acad Sci U S A. 2013 Apr 09; 110(15):6061-6.
    View in: PubMed
    Score: 0.028
  39. A new treatment for neurogenic inflammation caused by EV71 with CR2-targeted complement inhibitor. Virol J. 2012 Nov 23; 9:285.
    View in: PubMed
    Score: 0.027
  40. CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Circ Res. 2011 Nov 11; 109(11):1290-301.
    View in: PubMed
    Score: 0.025
  41. Complement inhibition alleviates paraquat-induced acute lung injury. Am J Respir Cell Mol Biol. 2011 Oct; 45(4):834-42.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.